Clene Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Clene Inc. announced submission of a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS) treatment, based on neurofilament light chain biomarker data and clinical outcomes. The company is simultaneously preparing a confirmatory Phase 3 RESTORE-ALS study. No financial figures, partnership details, or specific efficacy data are disclosed in this announcement.
Why this rating
NDA submission is material regulatory milestone for $40.4M biotech; accelerated approval pathway raises near-term approval odds substantially, but execution risk remains high and approval is uncertain.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.